Amgen Takes Almost 40% Of US Bevacizumab Market
As Company Launches Biosimilar Infliximab In US
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.
You may also be interested in...
Cipla launched its generic version of Amgen’s Sensipar ‘at risk’ in March last year after suing the originator and Teva over an earlier agreement between the pair. The suit has now been settled, although claims against Teva remain standing.
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.